CORDIS
EU research results

CORDIS

English EN
Eliciting Mucosal Immunity to Tuberculosis

Eliciting Mucosal Immunity to Tuberculosis

Objective

Tuberculosis (TB) is a global health problem, killing 1.5 million of people every year. The only currently available vaccine, Mycobacterium bovis BCG, is effective against severe childhood forms, but it demonstrates a variable efficacy against the pulmonary form of TB in adults. Many of these adult TB cases result from the reactivation of an initially controlled, latent Mycobacterium tuberculosis (MTB) infection. Effective prophylactic vaccination remains the key long-term strategy for combating TB. Continued belief in reaching this goal requires unrelenting innovation in the formulation and delivery of candidate vaccines. It is also based on the assumption, that the failure of recent human vaccine trials could have been due to a sub-optimal vaccine design and delivery, and therefore should not erode the key principle that a TB vaccine is an attainable target. This proposal focuses on mucosal vaccination, which has been considered in the past, but not implemented efficiently. The innovation of the proposal is focused on several important aspects of vaccine development and testing, including the use of novel technologies for vaccine delivery, novel ways of specific targeting of mucosal immune cells and tissues, the use of polypeptides incorporating early and latent MTB antigens and putative CD8+ T cell epitopes, and application of novel tools for identifying early predictors and correlates of vaccine-induced protection. The overall objective is to design a vaccine that will induce a broad-ranging immune response to MTB both systemically and in the mucosa of the lungs, and provide the currently missing links in protective immunity to this pathogen.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ST GEORGE'S HOSPITAL MEDICAL SCHOOL

Address

Cranmer Terrace
Sw17 0re London

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 235 080

Participants (13)

Sort alphabetically

Sort by EU Contribution

Expand all

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 363 586

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 970 037

UNIVERSIDAD DE VIGO

Spain

EU Contribution

€ 670 000

LIONEX GMBH

Germany

EU Contribution

€ 408 350

AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO PAOLO GIACCONE DI PALERMO

Italy

EU Contribution

€ 320 000

SPOREGEN LIMITED

United Kingdom

EU Contribution

€ 436 047

STOCKHOLMS UNIVERSITET

Sweden

EU Contribution

€ 333 350

AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS

Spain

EU Contribution

€ 323 036

UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA

Italy

EU Contribution

€ 320 132

INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL

Spain

EU Contribution

€ 184 792

Department of Health

United Kingdom

EU Contribution

€ 824 657

Instituto Nacional de Saúde

Mozambique

EU Contribution

€ 454 593

MIKROBIOLOGICKY USTAV - AVCR, V.V.I.

Czechia

EU Contribution

€ 150 000

Project information

Grant agreement ID: 643558

Status

Ongoing project

  • Start date

    1 January 2015

  • End date

    30 June 2019

Funded under:

H2020-EU.3.1.2.

  • Overall budget:

    € 7 999 920,11

  • EU contribution

    € 7 993 660

Coordinated by:

ST GEORGE'S HOSPITAL MEDICAL SCHOOL

United Kingdom